에서 실시간으로 운영 중이에요! 자세히 알아보기

Gilead Sciences

GILD

시가총액 US$1937억

156.19 USD

-1.18

0.75%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

156.84

+0.65

0.42%

1일

-0.75%

5일

2.86%

1개월

5.76%

3개월

14.59%

6개월

12.73%

연초 이후

28.45%

1년

32.53%

5년

137.01%

10년

115.02%

소개: Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

직원 수: 17,000

건강관리 제약 - 종합

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 55.6%

중립 37%

부정적 7.4%

Zacks Investment Research

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts

Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for o.

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Zacks Investment Research

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?

Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

The Big 3: MRK, GILD, XOM

The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a stabilizing healthcare sector, Gilead Sciences (GILD) as a stock "poised to continue upward price action," and Exxon Mobil (XOM) as a high-liquid name in a booming energy trade.

The Big 3: MRK, GILD, XOM

Zacks Investment Research

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

24/7 Wall Street

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Zacks Investment Research

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Zacks Investment Research

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.